Galmed Pharma (GLMD) Reports Q4 Loss of $0.40/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. MRK
7. LVS
8. SAP
9. CSX
10. LRCX

Go back to Galmed Pharma (GLMD) Reports Q4 Loss of $0.40/Share

Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results

March 23, 2017 7:30 AM EDT

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases, today reported financial results for the three and twelve months ended December 31, 2016, and announced new and exciting data from recently completed pre-clinical studies demonstrating Aramchol's potential direct effect on liver fibrosis. The data will be presented at the International Liver Congress 2017, to be held from April 19 to the 23rd... More